NCT05269940已完成1 期
A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematological Malignancies
Nanjing Zenshine Pharmaceuticals3 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年2月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 3
- 主要终点
- Defining the RP2D of ZX-101A
研究概览
简要总结
ZX-101A-202 is a Phase I, open-label, multicenter study, a single-agent dose-escalation and dose-expansion study of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacokinetics, efficacy and antitumor activity of ZX-101A in patients with relapsed/refractory hematological malignancies.
详细描述
Phase I includes two parts: dose escalation and dose expansion. It's mainly to explore the safety and tolerability of ZX-101A in patients with relapsed/ refractory hematological malignancies [Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL), indolent NHL, and other NHL subtypes], and to determine RP2D.
- Part 1. ZX-101A dose escalation
- Part 2. ZX-101A dose expansion in two specific types of lymphoma, i.e. PTCL /CTCL or one B-iNHL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females who are ≥ 18 years old
- •Minimum life expectancy ≥ 3 months (determined by investigator assessment)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Histopathological and cytological confirmed diagnosis of hematological malignancies.
- •Phase I dose expansion and phase II studies require at least 1 measurable lesion, including cutaneous T-cell lymphoma [CTCL] without evidence of skin involvement.
- •Acceptable bone marrow function.
- •Acceptable organ function: creatinine clearance ≥ 60 mL/min calculated according to institutional standard practice assessment (according to the Cockcroft-Gault formula) for kidney function; AST and ALT ≤ 2.5 x upper limit of normal (ULN) (AST and ALT ≤ 4 x ULN in subjects with liver involvement); total bilirubin ≤ 1.5 x ULN (total bilirubin ≤ 3 in subjects with Gilbert syndrome ×ULN) for liver function.
- •No transfusion or cytokine support for ≥ 2 weeks before first dosing.
- •Ability to swallow oral medication.
- •Negative serum pregnancy test in women of childbearing potential at screening.
- •Females of childbearing potential and males with female partners of childbearing potential must agree to use effective contraception during the study period and for 6 months (females) or 3 months (males) after the last dose of ZX-101A.
- •Men must agree to no sperm donation during the study and for 3 months after the last dose of ZX-101A.
- •Understands the requirements of the study, is willing to comply with all study procedures and signed the IRB-approved informed consent.
排除标准
- •Previous use of PI3K δ/γ dual inhibitors
- •Received approved anti-cancer drugs within 28 days (42 days for nitrosoureas) or 5 half-lives, whichever is longer.
- •Radiation treatment within 2 weeks prior to first dose of study treatment.
- •Received investigational study drug within 28 days (or 5 half-lives, whichever is longer).
- •Received organ transplantation in the past (hematopoietic stem cell transplantation in the past is allowed).
- •Major surgery within 28 days prior to the first dose of study drug
- •Has not recovered from adverse events from prior anti-cancer treatment (with exception of alopecia).
- •Concurrent participation in another therapeutic treatment trial.
- •Those who have been vaccinated with live vaccines or live attenuated vaccines within 30 days before the first administration, and seasonal influenza vaccines without live viruses are allowed.
- •Received warfarin or factor Xa inhibitor within 5 half-lives before the first dose of study drug.
- •With central nervous system (CNS) involvement or active leptomeningeal disease.
- •History of other malignancy within the past 5 years, unless cured by surgery and sustained disease-free survival.
- •CLL with Richter transformation.
- •Active autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)
- •Chronic immunosuppression conditions.
- •QTcF interval > 480 msec; echocardiographic detection of left ventricular ejection fraction < 45%.
- •Uncontrolled systemic diseases, including myocardial infarction or bypass, stent surgery, or other heart disease, in the judgement of the investigator, inappropriate for enrollment.
- •Active uncontrolled infection within 14 days before first dosing.
- •Active infection of Hepatitis B virus or hepatitis C virus; history of HIV infection.
- •History of drug-induced liver injury, chronic active hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, persistent extrahepatic obstruction due to gallstones, cirrhosis or portal vein history of hypertension.
- •History of interstitial lung disease, hypersensitivity pneumonitis, pulmonary fibrosis, radiation pneumonitis and severe pulmonary function impairment, or other pulmonary diseases that significantly affect the safety or compliance of patients after being evaluated and included by the investigator.
- •Gastrointestinal dysfunction, including motility or malabsorption syndromes or inflammatory bowel disease which could limit absorption of study drug.
- •Any concurrent uncontrolled illness, including mental illness or substance abuse.
研究组 & 干预措施
ZX-101A Dose Level B
Experimental
ZX-101A administered orally at level B once daily
干预措施: ZX-101A (Drug)
ZX-101A Dose Level E
Experimental
ZX-101A administered orally at level E once daily
干预措施: ZX-101A (Drug)
ZX-101A Dose Level D
Experimental
ZX-101A administered orally at level D once daily
干预措施: ZX-101A (Drug)
ZX-101A Dose Level C
Experimental
ZX-101A administered orally at level C once daily
干预措施: ZX-101A (Drug)
ZX-101A Dose Level A
Experimental
ZX-101A administered orally at level A once daily
干预措施: ZX-101A (Drug)
结局指标
主要结局
Defining the RP2D of ZX-101A
时间窗: From Day 1 of Cycle 1 (each cycle is 28 days) until 28 days after the last dose (up to 2 years)
To assess number of patients experiencing dose-limiting toxicities (DLTs)
To examine the incidence of clinical and laboratory adverse events after multiple doses of ZX-101A
时间窗: From Day 1 of Cycle 1 (each cycle is 28 days) until 28 days after the last dose (up to 2 years)
Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\]
次要结局
- Duration of response (DoR)(Up to 2 years)
- Progression free survival (PFS)(Up to 2 years)
- Overall survival (OS)(Up to 2 years)
- Plasma Concentration of ZX-101A(Cycle1Day1 pre-dose and post-dose 0.5, 1 , 2, 4, 6, 8, 24, 48, 72, 96 hours; Cycle1Day13, Day14, Day15 pre-dose and post-dose 0.5, 1, 2, 4 , 6, 8 and 24 hours; Cycle2Day1 pre-dose. Each cycle is 28 days.)
- Objective response rate (ORR)(Up to 2 years)
- Phospho-AKT (p-AKT) levels in whole blood(Cycle1Day1 pre-dose and post-dose 1 hour and 24 hours. Each Cycle is 28 days.)
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
1 期
A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid TumorsAdvanced Solid TumorNCT05258266Nanjing Zenshine Pharmaceuticals76
终止
1 期
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic MalignanciesSmall Lymphocytic LymphomaNon-hodgkin LymphomaChronic Lymphocytic LeukemiaNCT04504708Hangzhou Zenshine Pharmaceuticals Co., Ltd.6
已完成
1 期
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue SarcomasDose Escalation: Solid TumorsMTD: Soft Tissue SarcomasNCT00878800Valerio Therapeutics41
Unknown
1 期
A Phase I/II Study of XZP-3287 in Metastasis Solid TumorsMetastasis Solid TumorsAdvanced Breast CancerNCT04539496Sihuan Pharmaceutical Holdings Group Ltd.300
已完成
1 期
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive TherapyAcute Myeloid LeukemiaNCT00878722Valerio Therapeutics41